Phlow Market Share Analysis for June 2026

Validation Completed for a Novel, Cost-Competitive Epinephrine Active Pharmaceutical Ingredient Process, Drug Master File Successfully Filed Richmond, Virginia, March 17, 2025 — Phlow Corp., a U.S.-based certified B Corporation on a mission to bring medicines to life through advanced development and manufacturing in America, today announced a major milestone, achieving a successful process validation campaign for Epinephrine active pharmaceutical ingredient (API) production. This achievement positions Phlow to continue advancing toward full domestic production capabilities in its state-of-the-art U.S. facilities for this life-saving medicine. The company has filed a Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) — a critical regulatory step. This product is now ready to be converted into a finished drug product. The entirety of the Epinephrine API manufacturing campaign has been performed in the United States, further reinforcing Phlow’s commitment to reshoring modern medicine development and manufacturing and strengthening national health resilience. Phlow developed a manufacturing method leveraging novel chemistry that streamlines production, reducing both waste and manufacturing costs, while making the production of Epinephrine on U.S. soil cost competitive. Epinephrine, a life-saving generic medication, is used along with emergency medical treatment to help treat cardiac arrest, life-threatening low blood pressure associated with […]